GlassScriptPhysician profile
Lauren Barnes
NPI 1265851687
$9,926.75
in general payments reported to CMS, 2019-2025
32 companies · $2,367 in 2025
The $2,367 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $1,074 · 2021: $1,350 · 2022: $1,503 · 2023: $1,245 · 2024: $1,989 · 2025: $2,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,630 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $873 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,629.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $872.81 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,762.39 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Janssen Biotech, INC. | $838.71 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $722.86 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Allergan, INC. | $717.16 | 2020-2022 | |
| Amgen INC. | $626.30 | 2020-2025 | Otezla, Otezla, Enbrel |
| Regeneron Healthcare Solutions, INC. | $589.18 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $566.47 | 2020-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $516.35 | 2020-2025 | |
| Ucb, INC. | $409.16 | 2019-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $342.68 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $283.65 | 2020-2025 | Absorica Ld, Winlevi |
| Pfizer INC. | $278.29 | 2019-2025 | |
| Leo Pharma INC. | $243.88 | 2019-2025 | Adbry |
| Biofrontera INC. | $133.62 | 2020-2024 | Ameluz, Rhodoled Xl, Xepi |
| Vyne Pharmaceuticals INC. | $108.89 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hill Dermaceuticals, INC. | $108.23 | 2024 | Tolak |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $107.86 | 2019-2021 | |
| Dermavant Sciences, INC. | $90.69 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $72.41 | 2022-2023 | Sotyktu |
| Verrica Pharmaceuticals INC. | $61.18 | 2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.49 | 2022-2023 | Spevigo |
| Genzyme Corporation | $50.46 | 2020-2024 | |
| Almirall LLC | $40.41 | 2020-2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $38.44 | 2024 | |
| Revance Therapeutics, INC. | $28.21 | 2024 | Daxxify |
| Epi Health, LLC | $24.81 | 2021 | |
| Dermira, INC. | $21.98 | 2020 | |
| Merck Sharp & Dohme LLC | $21.84 | 2022 | |
| Blueprint Medicines Corporation | $17.33 | 2024 | Ayvakit |
| Arcutis Biotherapeutics, INC. | $16.15 | 2024 | Zoryve |
| Krystal Biotech INC | $15.52 | 2023 | Vyjuvek |
| Fresenius Kabi USA, LLC | $13.15 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.